Pharmaceuticals News and Research

RSS

Innophos reports net sales of $209 million for fourth quarter 2012

Innophos Holdings, Inc., a leading international producer of performance-critical and nutritional specialty ingredients, with applications in food, beverage, dietary supplements, pharmaceutical, oral care and industrial end markets, today announced its financial results for the fourth quarter and full year 2012.

14 Feb 2013

Regeneron fourth quarter total revenues increase to $415 million

Regeneron Pharmaceuticals, Inc. today announced financial and operating results for the fourth quarter and full year 2012 and provided an update on development programs.

14 Feb 2013

Tianyin Pharmaceutical second quarter revenue decreases 3.3% to $17.6 million

Tianyin Pharmaceutical Inc., a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for second quarter of the fiscal year 2013.

14 Feb 2013

GSK1322322 targets gram-positive bacteria including methicillin-resistant strains of MRSA

An increasing number of bacteria is evolving antibiotic resistance. Much-feared representatives of this steadily growing group include Staphylococci strains. At this point, multi-resistant forms of the bacterium Staphylococcus aureus - the "hospital germ" known commonly by its acronym, MRSA - can only be treated with a select subset of antibiotics as many drugs have simply stopped working. This is precisely why the field of medicine is in desperate need of new treatment options.

14 Feb 2013

Traumatic brain injury investigational treatment from BHR Pharma receives EMA orphan medicinal product designation

BHR Pharma, LLC announced today the European Medicines Agency (EMA), responsible for evaluating medicines developed for use in the European Union, granted an orphan medicinal product designation for treating moderate and severe traumatic brain injury (TBI) to its proprietary intravenous progesterone infusion agent, BHR-100. The agent currently is being evaluated as a neuroprotective treatment for severe traumatic brain injury (TBI) in the global, Phase III SyNAPSe® clinical trial.

14 Feb 2013

As part of 'expansive' agenda, Obama offers support for 'modest' Medicare reforms

In last night's State of the Union address, President Barack Obama offered his take on how the U.S. budget could achieve "fiscal stability" through a mix of Medicare cuts and tax increases; however, he provided few details of what changes to Medicare he found acceptable.

14 Feb 2013

Targacept reports net loss of $15.9 million for fourth quarter 2012

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today reported its financial results for the fourth quarter and year ended December 31, 2012.

14 Feb 2013

New paper advances scientific understanding of glycoproteins’ structure and function

A Simon Fraser University chemist is the lead author on a new paper that advances scientific understanding of the structure and function of glycoproteins, in particular the number and positioning of sugars on them.

14 Feb 2013

FDA grants final approval to Breckenridge’s Pioglitazone Hydrochloride ANDA

Breckenridge Pharmaceutical, Inc. announced today the immediate launch of Pioglitazone Hydrochloride Tablets. The U.S. Food and Drug Administration granted final approval for the Abbreviated New Drug Application (ANDA), which is being manufactured and supplied by Synthon Pharmaceuticals, Inc., and will be available in 15 mg, 30 mg, and 45 mg strengths.

14 Feb 2013

Government recovers billions in health fraud crackdown

The Obama administration announced Monday that it recovered a record $4.2 billion last year from medical providers who cheated Medicare and other government health programs.

13 Feb 2013

Antibody therapeutics targeting GPCRs to be developed by alliance between MorphoSys and Heptares

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) and UK-based Heptares Therapeutics, the leading GPCR drug discovery and development company, have signed an agreement to discover novel antibody therapeutics targeting G protein-coupled receptors (GPCRs), which are membrane proteins involved in a broad range of biological processes and diseases.

13 Feb 2013

Big Pharma looks to Africa for next growth market as economies strengthen, disease burden shifts

"Not only is Africa's economic growth grabbing attention in boardrooms but the shifting nature of its disease burden is luring Big Pharma, as new opportunities open up for treating chronic diseases afflicting the middle classes, rather than just fire-fighting infection," Reuters reports.

13 Feb 2013

Underwriters Laboratories announces new non-clinical lab, resources and capabilities for biocompatibility in North America

UL (Underwriters Laboratories), a world leader in advancing safety, announced today the expansion of the South Bend, Indiana analytical laboratory to offer non-clinical testing services for the medical device industry.

13 Feb 2013

Sucampo, R-Tech Ueno and Takeda file patent infringement lawsuit against Anchen for AMITIZA

Sucampo Pharmaceuticals, Inc. announced that it, together with R-Tech Ueno, Ltd., Sucampo AG, and Takeda Pharmaceutical Company Limited and certain affiliates of Takeda, has filed a patent infringement lawsuit against Anchen Pharmaceuticals, Inc., which had filed Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) to market a generic version of AMITIZA (lubiprostone) oral capsules, and certain affiliates of Anchen.

12 Feb 2013

Florida Hospital, Sanford-Burnham and Takeda renew research agreement

Sanford-Burnham Medical Research Institute (Sanford-Burnham) and Florida Hospital announced today that they have renewed a research agreement with Takeda Pharmaceutical Company Limited (Takeda) to extend their collaboration to discover and evaluate new therapeutic approaches to obesity. The collaboration uses a research and drug-development model that creates an early feedback loop in the discovery pipeline.

12 Feb 2013

Enzyme therapy slows progression of Batten disease in dogs

Batten disease is a rare, fatal genetic disorder that affects children. Currently, no effective treatment exists for the disease, which ultimately kills all who are affected. Dachshunds also suffer from Batten disease, and now researchers from the University of Missouri College of Veterinary Medicine and School of Medicine, in collaboration with BioMarin Pharmaceutical Inc., have developed a treatment for the disease that has significantly delayed the onset and progression of symptoms in the Dachshunds.

12 Feb 2013

Unilife revenues decrease to $0.7 million for three months ended December 31, 2012

Unilife Corporation, a developer and supplier of injectable drug delivery systems, today announced its financial results for the quarter ended December 31, 2012, (the second quarter of Fiscal Year 2013).

12 Feb 2013

Parenteral nutrition safety: an interview with Dr. Phil Ayers, A.S.P.E.N PN Safety Task Force Chair and Dr. Peggi Guenter, Director of the American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.)

Parenteral nutrition is intravenous nutrition for patients who are unable to eat or be tube fed. It is used with more than 300,000 patients per year - a quarter of whom are children and newborns.

11 Feb 2013

FDA issues draft guidance on developing new treatments for Alzheimer's

Today, the U.S. Food and Drug Administration issued a proposal designed to assist companies developing new treatments for patients in the early stages of Alzheimer's disease, before the onset of noticeable (overt) dementia.

11 Feb 2013

Scientists demonstrate new approach for quickly assembling drug-like compounds

A team of scientists anchored at Yale University has demonstrated a new, highly versatile approach for quickly assembling drug-like compounds, establishing a broad new route to drug discovery and medical treatment.

11 Feb 2013

Pharmaceuticals News and Research

Innophos reports net sales of $209 million for fourth quarter 2012

Regeneron fourth quarter total revenues increase to $415 million

Tianyin Pharmaceutical second quarter revenue decreases 3.3% to $17.6 million

GSK1322322 targets gram-positive bacteria including methicillin-resistant strains of MRSA

Traumatic brain injury investigational treatment from BHR Pharma receives EMA orphan medicinal product designation

As part of 'expansive' agenda, Obama offers support for 'modest' Medicare reforms

Targacept reports net loss of $15.9 million for fourth quarter 2012

New paper advances scientific understanding of glycoproteins’ structure and function

FDA grants final approval to Breckenridge’s Pioglitazone Hydrochloride ANDA

Government recovers billions in health fraud crackdown

Antibody therapeutics targeting GPCRs to be developed by alliance between MorphoSys and Heptares

Big Pharma looks to Africa for next growth market as economies strengthen, disease burden shifts

Underwriters Laboratories announces new non-clinical lab, resources and capabilities for biocompatibility in North America

Sucampo, R-Tech Ueno and Takeda file patent infringement lawsuit against Anchen for AMITIZA

Florida Hospital, Sanford-Burnham and Takeda renew research agreement

Enzyme therapy slows progression of Batten disease in dogs

Unilife revenues decrease to $0.7 million for three months ended December 31, 2012

Parenteral nutrition safety: an interview with Dr. Phil Ayers, A.S.P.E.N PN Safety Task Force Chair and Dr. Peggi Guenter, Director of the American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.)

FDA issues draft guidance on developing new treatments for Alzheimer's

Scientists demonstrate new approach for quickly assembling drug-like compounds

Pittcon Highlights: Pharmaceutical & Biologic eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence